Talphera, Inc.
HAYWARD, California, United States · Biotechnology, Healthcare, Health Care
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, an
Key facts
- Headquarters
- HAYWARD, California, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (TLPH)
- Website
- www.acelrx.com
- Company page
Recent activity at Talphera, Inc.
- : SEC 8-K (5.02): On June 22, 2026, during the Annual Meeting of Stockholders of Talphera, Inc., stockholders approved the election of three directors: Marina Bozilenko, Joseph Todisco, and Mark Wan, who will serve until the 2029 Annual Meeting. The election witnessed a substantial vote with Marina Bozilenko receiving 23,303,306 votes in favor and a total representation of 31,436,937 shares during the meeting. Additionally, the meeting ratified BPM LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. This shift in board members and confirmation of auditors reflects strategic governance changes aimed at fortifying the Board's oversight and future direction of the Company.
- : SEC 8-K (3.01): On March 11, 2026, Talphera, Inc. received a notice from the Listing Qualifications Staff of the Nasdaq Stock Market indicating that the company is not in compliance with the minimum bid price requirement of $1.00 per share as specified in Nasdaq Listing Rule 5550(a)(2). The notice states that the deficiency exists due to the stock’s failure to meet the minimum bid price for 30 consecutive business days. However, the notification does not affect the current listing of the company's common stock on Nasdaq, which will remain while the company has 180 calendar days to regain compliance. This situation could have strategic implications for the company’s market position and investor confidence.
- : SEC 8-K (5.02): On October 23, 2025, during the Annual Meeting of Stockholders for Talphera, Inc., the stockholders approved an amendment and restatement of the Company's Amended and Restated 2020 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan. The meeting included the election of Vincent J. Angotti, Stephen J. Hoffman, M.D., Ph.D., and Abhinav Jain as Class II directors, who will serve until the 2028 Annual Meeting. The total number of shares represented at the meeting was 9,778,006 out of the 20,522,655 shares entitled to vote. In addition, BPM LLP was ratified as the Company’s independent registered public accounting firm for the year ending December 31, 2025, with significant votes for and against the proposals discussed.
- : SEC 8-K (8.01): On October 20, 2025, Talphera, Inc. was notified by Nasdaq that it had regained compliance with the minimum bid price requirement of $1.00 per share, following a period where the stock price closed below that threshold for 30 consecutive business days. This compliance was achieved as the closing bid price had been above $1.00 for at least 10 consecutive business days ending October 17, 2025. Talphera had previously transferred to the Nasdaq Capital Market to regain eligibility for additional compliance periods, and now with the new compliance status, it strengthens the financial positioning of the company in the capital markets. This notification is an important step in maintaining Talphera's listing status on the exchange.
- : SEC 8-K (8.01): On October 21, 2025, Talphera, Inc. entered into an Optional Closing of a previously disclosed securities purchase agreement with several institutional investors and a member of management. This agreement involves the issuance and sale of 1,023,890 shares of common stock at a purchase price of $0.586 per share as part of a private placement structured in three tranches. The conditions of certain subsections were waived to facilitate this second and third closing of the transaction. The initial closing of the private placement had taken place on April 2, 2025, indicating ongoing capital raising efforts by Talphera to strengthen its financial position.
- : SEC 8-K (5.02): On October 14, 2025, Talphera, Inc. appointed Joseph Todisco as a Class III member of its board of directors and member of the compensation committee. Mr. Todisco, the CEO of CorMedix Inc., brings extensive experience from his previous roles at Amneal Pharmaceuticals and other notable companies. In connection with his appointment, it was approved on October 15, 2025, that he would receive 6,397 restricted stock units and options for 38,381 shares of common stock at an exercise price of $1.11 per share, which will vest over three years. Additionally, a non-employee director indemnification agreement will be entered into with him, solidifying his governance role.
- : ACELRX PHARMACEUTICALS
- : ACELRX PHARMACEUTICALS
- : ACELRX PHARMACEUTICALS
- : ACELRX PHARMACEUTICALS
Talphera, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Venture | $17.0M |
| Apr 2025 | Seed | $4.9M |
| Jul 2023 | Venture | $10.0M |
| Aug 2022 | Venture | $630K |
| Jan 2022 | Venture | $5.2M |
Leadership
- Mark Wan, Director
- Howard Rosen, Director
- Stephen Hoffman, Director
- Marina Bozilenko, Director
- Jill Broadfoot, Director
- Richard Afable, Director
- Adrian Adams, Director
- Pamela Palmer, Executive Officer, Director
- Vincent Angotti, Executive Officer, Director
Verified email and direct lines for Talphera, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Talphera, Inc. files 5 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Talphera, Inc. in the news
Companies similar to Talphera, Inc.
- valisure llc · Biotechnology, Healthcare, Health Care, Manufacturing, Pharmaceutical
- Ionetix Corp · Biotechnology, Healthcare, Health Care, Manufacturing, Pharmaceutical
- AbbVie Inc. · Biotechnology, Healthcare, Health Care, Manufacturing, Pharmaceutical
- Optimi Health · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- Catalent Pharma Solutions · Biotechnology, Healthcare, Health Care, Manufacturing
About Talphera, Inc.: questions and answers
What does Talphera, Inc. do?
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, an
Where is Talphera, Inc. headquartered?
Talphera, Inc. is headquartered in HAYWARD, California, United States.
Has Talphera, Inc. raised funding?
Yes. Fundz has recorded 5 funding events for Talphera, Inc.. The most recent, $17.0M, was in Sep 2025.
What is the latest news on Talphera, Inc.?
On Jun 23, 2026, SEC 8-K (5.02): On June 22, 2026, during the Annual Meeting of Stockholders of Talphera, Inc., stockholders approved the election of three directors: Marina Bozilenko, Joseph Todisco, and Mark Wan, who will serve until the 2029 Annual Meeting. The election witnessed a substantial vote with Marina Bo
Is Talphera, Inc. a public company?
Yes. Talphera, Inc. is publicly traded under the ticker TLPH.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy